B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus

Paola Tomietto; Elisa Gremese; Barbara Tolusso; Paolo Venturini; Salvatore De Vita; Gianfranco Ferraccioli

doi:10.1055/s-0037-1614293

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 92(05): 1150-1153
DOI: 10.1055/s-0037-1614293

Case Report

Schattauer GmbH

B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus

Paola Tomietto

¹Division of Rheumatology, Catholic University of the Sacred Heart Rome-UCSC, Rome, Italy

,

Elisa Gremese

¹Division of Rheumatology, Catholic University of the Sacred Heart Rome-UCSC, Rome, Italy

,

Barbara Tolusso

¹Division of Rheumatology, Catholic University of the Sacred Heart Rome-UCSC, Rome, Italy

,

Paolo Venturini

²University of Udine-DPMSC-Udine, Italy

,

Salvatore De Vita

²University of Udine-DPMSC-Udine, Italy

,

Gianfranco Ferraccioli

²University of Udine-DPMSC-Udine, Italy

References
1 Perrotta S, Locatelli F, La AManna. et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 16 (02) 465-7.
2 Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484-92.
3 Stasi R, Pagano A, Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
4 Pestronk A, Florence J, Miller T. et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74 (04) 485-9.
5 Zaja F, Russo D, Fuga G. et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-3.
6 Leandro MJ, Edwards JC, Cambridge G. et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-77.
7 Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783-7.
8 Weide R, Heymanns J, Pandorf A. et al. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779-82.
9 Saito K, Nawata M, Nakayamada S. et al. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798-800.
10 Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206 (05) 519-27.
11 Tren SP, Agus DB, Link B. et al. CD20-directed antibody-mediated immunotheraphy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia. J Immunother 2001; 24: 272-9.
12 Specks U, Fervenza FC, McDonald TJ. et al. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40.
13 Slifka MK, Antia R, Whitmire JK. et al. Humoral immunity due to long-lived plasma cells. Immunity 1998; 08: 363-72.
14 Ten Cate R, Smiers FJ, Bredius RGM. et al. Anti-CD-20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus.. Rheumatology 2004; 43: 244.